Table 2b.

Symptom prevalence by SARS-CoV-2 serological status after excluding SARS-CoV-2 RNA-positive participants (n = 10 899).

	Seropositive (n = 212)					Seronegative (n = 10 687)
Symptoms	Reported symptoms		One or more symptoms persisting ≥ 30 daysa		Reported symptoms overall persisting ≥ 30 daysb	Reported symptoms		One or more symptoms persisting ≥ 30 daysa		Reported symptoms overall persisting ≥ 30 daysb
	Number	%	Numberc	%	%	Number	%	Numberc	%	%
Loss of sense of taste and smell	59	28	18 (58)	31	9	292	3	93 (285)	33	1
Fever	79	37	20 (77)	26	10	1178	11	215 (1151)	19	2
Dyspnoea	32	15	15 (31)	48	7	605	6	212 (586)	36	2
Muscle or joint ache	78	37	22 (75)	29	11	1716	16	450 (1639)	27	4
Fatigue	95	45	24 (92)	26	12	2596	24	660 (2484)	27	6
Cough	73	34	20 (72)	28	10	2349	22	695 (2265)	31	7
Headache	112	53	26 (109)	24	13	4056	38	901 (3904)	23	9
Sore throat	76	36	19	25	9	3152	29	673 (2044)	22	6

	Seropositive (n = 212)				Seronegative (n = 10 687)
	Reported any symptom		Reported any symptom persisting ≥ 30 days		Reported any symptom		Reported any symptom persisting ≥ 30 days
	Number	%	Numberc	%	Number	%	Numberc	%
	159	75	40 (156)	26	5920	55	1331 (5678)	23

Data presented as numbers with percentages.

^aNumber of participants reporting one or more symptoms persisting for more than 30 days among participants reporting the specific symptom.

^bPercentage of participants who both report the specific symptom and report one or more symptoms persisting after 30 days.

^cNumbers in parentheses represent participants reporting the symptom (corresponding to the number of “Reported symptoms”) but excluding participants whose symptoms started within 30 days completing of the questionnaire (n = 243) in addition to participants with discrepancy between symptom start date and symptom end date (n = 44). In total, 285 participants were excluded.